A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

Future Oncology, Ahead of Print.

Source: Future Oncology - September 11, 2019 Category: Cancer & Oncology Authors: Philip A Philip Marc E Buyse Angela T Alistar Caio MSPR Lima Sanjeev Luther Timothy S Pardee Eric Van Cutsem Source Type: research